Childhood brain tumors: Epidemiology, current management and future directions

Nature Reviews Neurology

Volumn 7, Issue 9, 2011, Pages 495-506

  Pollack, Ian F ^a   Jakacki, Regina I ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; LOMUSTINE; PROCARBAZINE; TIOGUANINE; VINCRISTINE;

BRAIN STEM GLIOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ENVIRONMENTAL FACTOR; EPENDYMOMA; HEREDITY; HIGH GRADE GLIOMA; HIGH RISK POPULATION; HUMAN; LOW GRADE GLIOMA; MEDULLOBLASTOMA; MORBIDITY; NEUROECTODERM TUMOR; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; INFANT; INFANT, NEWBORN; NEUROSURGERY; RISK FACTORS;

EID: 80052495946     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.110     Document Type: Review

References (143)

1. Pollack, I. F. Brain tumors in children. N. Engl. J. Med. 331, 1500-1507 (1994). (Pubitemid 24356310)
2. Howlader, N. et al. SEER cancer statistics review, 1975-2008 National Cancer Institute [online], http://seer.cancer.gov/csr/1975-2008/index.html (2011).
3. Packer, R. J. et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 24, 4202-4208 (2006). (Pubitemid 46622300)
4. Wisoff, J. H. et al. Primary neurosurgery for pediatric low-grade astrocytomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery 68, 1548-1555 (2011).
5. Jennings, M. T. et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J. Clin. Oncol. 20, 3431-3437 (2002).
6. Cohen, K. J. et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 13, 410-416 (2011).
7. Cohen, K. J. et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 13, 317-323 (2011).
8. Hjalmars, U., Kulldorff, M., Wahlqvist, Y. & Lannering, B. Increased incidence rates but no space-time clustering of childhood astrocytoma in Sweden, 1973-1992: a population-based study of pediatric brain tumors. Cancer 85, 2077-2090 (1999). (Pubitemid 29202785)
9. Makino, K., Nakamura, H., Yano, S. & Kuratsu, J. Population-based epidemiological study of primary intracranial tumors in childhood. Childs Nerv. Syst. 26, 1029-1034 (2010).
10. Feltbower, R. G. et al. Epidemiology of central nervous system tumors in children and young adults (0-29 years), Yorkshire, United Kingdom. Pediatr. Hematol. Oncol. 21, 647-660 (2004). (Pubitemid 39336822)
11. Peris-Bonet, R. et al. Childhood central nervous system tumours-incidence and survival in Europe (1978-1997): report from Automated Childhood Cancer Information System project. Eur. J. Cancer 42, 2064-2080 (2006). (Pubitemid 44224055)
12. CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006 Central Brain Tumor Registry of the United States [online], http://www.cbtrus.org/2010-NPCR-SEER/ CBTRUS-WEBREPORT-Final-3-2-10.pdf (2010).
13. Suh, Y. L. et al. Tumors of the central nervous system in Korea: a multicenter study of 3221 cases. J. Neurooncol. 56, 251-259 (2002).
14. Linet, M. S., Ries, L. A., Smith, M. A., Tarone, R. E. & Devesa, S. S. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J. Natl Cancer Inst. 91, 1051-1058 (1999). (Pubitemid 29293044)
15. Smith, M. A., Freidlin, B., Ries, L. A. & Simon, R. Increased incidence rates but no space-time clustering of childhood astrocytoma in Sweden, 1973-1992: a population-based study of pediatric brain tumors. Cancer 85, 1492-1493 (1999).
16. Smith, M. A., Freidlin, B., Ries, L. A. & Simon, R. Trends in reported incidence of primary malignant brain tumors in children in the United States. J. Natl Cancer Inst. 90, 1269-1277 (1998). (Pubitemid 28433471)
17. Kuratsu, J. & Ushio, Y. Epidemiological study of primary intracranial tumors in childhood. A population-based survey in Kumamoto Prefecture, Japan. Pediatr. Neurosurg. 25, 240-246 (1996).
18. Linabery, A. M. & Ross, J. A. Trends in childhood cancer incidence in the U.S. (1992-2004).Cancer 112, 416-432 (2008).
19. Cohen, K. & Pollack, I. F. in Rudolph's Pediatrics (eds Rudolph, C. D. et al.) 1656-1660 (McGraw-Hill, New York, 2011).
20. Vinchon, M. et al. Radiation-induced tumors in children irradiated for brain tumor: a longitudinal study. Childs Nerv. Syst. 27, 445-453 (2011).
21. Baldwin, R. T. & Preston-Martin, S. Epidemiology of brain tumors in childhood-a review. Toxicol. Appl. Pharmacol. 199, 118-131 (2004). (Pubitemid 39094530)
22. Ron, E. et al. Tumors of the brain and nervous system after radiotherapy in childhood. N. Engl. J. Med. 319, 1033-1039 (1988).
23. Neglia, J. P. et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 325, 1330-1336 (1991).
24. Kheifets, L. et al. A pooled analysis of extremely low-frequency magnetic fields and childhood brain tumors. Am. J. Epidemiol. 172, 752-761 (2010).
25. Bunin, G. R., Robison, L. L., Biegel, J. A., Pollack, I. F. & Rorke-Adams, L. B. Parental heat exposure and risk of childhood brain tumor: A Children's Oncology Group study. Am. J. Epidemiol. 164, 222-231 (2006). (Pubitemid 44289043)
26. Haimi, M., Peretz Nahum, M. & Ben Arush, M. W. Delay in diagnosis of children with cancer: a retrospective study of 315 children. Pediatr. Hematol. Oncol. 21, 37-48 (2004). (Pubitemid 38101409)
27. Panigrahy, A., Nelson, M. D. Jr & Bluml, S. Magnetic resonance spectroscopy in pediatric neuroradiology: clinical and research applications. Pediatr. Radiol. 40, 3-30 (2010).
28. Kim, S., Salamon, N., Jackson, H. A., Bluml, S. & Panigrahy, A. PET imaging in pediatric neuroradiology: current and future applications. Pediatr. Radiol. 40, 82-96 (2010).
29. Finlay, J. L. et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J. Clin. Oncol. 13, 112-123 (1995).
30. Zeltzer, P. M. et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J. Clin. Oncol. 17, 832-845 (1999). (Pubitemid 29109313)
31. Moshel, Y., Elliott, R. E., Monoky, D. J. & Wisoff, J. H. Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma. J. Neurosurg. Pediatrics 4, 495-505 (2010).
32. Merchant, T. E. et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 10, 258-266 (2009).
33. Merchant, T. E. et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J. Clin. Oncol. 22, 3156-3162 (2004). (Pubitemid 41103730)
34. Merchant, T. E. et al. Preliminary results from a phase II trail of conformal radiation therapy for pediatric patients with localised low-grade astrocytoma and ependymoma. Int. J. Radiat. Oncol. Biol. Phys. 52, 325-332 (2002). (Pubitemid 34170841)
35. Radcliffe, J. et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann. Neurol. 32, 551-554 (1992).
36. Ellenberg, L., McComb, J. G., Siegel, S. E. & Stowe, S. Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery 21, 638-644 (1987). (Pubitemid 18001501)
37. MacDonald, S. M. et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int. J. Radiat. Oncol. Biol. Phys. 71, 979-986 (2008).
38. Merchant, T. E. et al. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr. Blood Cancer 51, 110-117 (2008). (Pubitemid 351717400)
39. Evans, A. E. et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J. Neurosurg. 72, 572-582 (1990). (Pubitemid 20113683)
40. Sposto, R. et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J. Neurooncol. 7, 165-177 (1989). (Pubitemid 19182070)
41. Tait, D. M., Thornton-Jones, H., Bloom, H. J., Lemerle, J. & Morris-Jones, P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I).Eur. J. Cancer 26, 464-469 (1990). (Pubitemid 20209976)
42. Ater, J. L. Results of COG protocol A9952: A randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol. 10, 451-452 (2008).
43. Lafay-Cousin, L. et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103, 2636-2642 (2005). (Pubitemid 40800545)
44. Packer, R. J. et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J. Neurosurg. 86, 747-754 (1997). (Pubitemid 27187674)
45. Fisher, B. J., Leighton, C. C., Vujovic, O., Macdonald, D. R. & Stitt, L. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 51, 704-710 (2001).
46. Hirsch, J. F., Sainte Rose, C., Pierre-Kahn, A., Pfister, A. & Hoppe-Hirsch, E. Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J. Neurosurg. 70, 568-572 (1989). (Pubitemid 19100717)
47. Pollack, I. F., Claassen, D., al-Shboul, Q., Janosky, J. E. & Deutsch, M. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J. Neurosurg. 82, 536-547 (1995).
48. Kortmann, R. D. et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: Treatment modalities of radiation therapy. Strahlenther. Onkol. 179, 509-520 (2003).
49. Mishra, K. K. et al. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J. Neurooncol. 100, 121-127 (2010).
50. Massimino, M. et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J. Neurooncol. 100, 65-71 (2010).
51. Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673-8677 (2008).
52. Pfister, S. et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Invest. 118, 1739-1749 (2008). (Pubitemid 351632377)
53. Raabe, E. H. et al. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin. Cancer Res. 17, 3590-3599 (2011).
54. Kolb, E. A. et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 55, 668-677 (2010).
55. Gururangan, S. et al. Efficacy of bevacizumab + CPT-11 in children with recurrent low-grade glioma (LGG)-a Pediatric Brain Tumor Consortium study. Neuro Oncol. (in press).
56. Warren, K. E. et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018 J. Clin. Oncol. 29, 324-329 (2011).
57. Lam, C. et al. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr. Blood Cancer 54, 476-479 (2010).
58. Krueger, D. A. et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811 (2010).
59. Li, M. et al. Frequent amplification of a chr19q1341 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 16, 533-546 (2009).
60. Pomeroy, S. L. et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002). (Pubitemid 34100955)
61. Gibson, P. et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468, 1095-1099 (2010).
62. Kool, M. et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3, e3088 (2008).
63. Northcott, P. A. et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 29, 1408-1414 (2011).
64. Parsons, D. W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439 (2011).
65. Thompson, M. C. et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 24, 1924-1931 (2006). (Pubitemid 46638992)
66. Louis, D. N. et al. The WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109 (2007). (Pubitemid 47103521)
67. Pizer, B. L. et al. Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur. J. Cancer 42, 1120-1128 (2006).
68. Taylor, R. E. et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur. J. Cancer 41, 727-734 (2005). (Pubitemid 40342556)
69. Thomas, P. R. et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J. Clin. Oncol. 18, 3004-3011 (2000). (Pubitemid 30644125)
70. Packer, R. J. et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J. Clin. Oncol. 17, 2127-2136 (1999). (Pubitemid 29318845)
71. US National Library of Medicine. Comparison of radiation therapy regimens in combination with chemotherapy in treating young patients with newly diagnosed standard-risk medulloblastoma. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00085735?term=NCT00085735&rank=1 (2011).
72. Tabori, U. et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J. Clin. Oncol. 28, 1345-1350 (2010).
73. Von Hoff, K. et al. Outcome according to Myc status, histopathological, and clinical risk factors. Pediatr. Blood Cancer 54, 369-376 (2009).
74. Miralbell, R. et al. Radiotherapy in pediatric medulloblastoma: quality assessment of Pediatric Oncology Group Trial 9031 Int. J. Radiat. Oncol. Biol. Phys. 64, 1325-1330 (2006).
75. Gajjar, A. et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol.7, 813-820 (2006). (Pubitemid 44464063)
76. Jakacki, R. et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR).J. Clin. Oncol. 25, 75S (2007).
77. US National Library of Medicine. Chemotherapy and radiation therapy in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00392327? term=NCT00392327&rank=1 (2011).
78. Raffel, C. et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 57, 842-845 (1997). (Pubitemid 27098006)
79. Berman, D. M. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559-1561 (2002). (Pubitemid 34971004)
80. Romer, J. & Curran, T. Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res. 65, 4975-4978 (2005). (Pubitemid 40827300)
81. Rudin, C. M. et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 N. Engl. J. Med. 361, 1173-1178 (2009).
82. US National Library of Medicine. GDC-0449 in treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00822458? term=NCT00822458&rank=1 (2010).
83. Horn, B. et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J. Pediatr. Hematol. Oncol. 21, 203-211 (1999). (Pubitemid 30306031)
84. Robertson, P. L. et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J. Neurosurg. 88, 695-703 (1998). (Pubitemid 28145213)
85. Merchant, T. E. et al. Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int. J. Radiat. Oncol. Biol. Phys. 53, 52-57 (2002). (Pubitemid 34465807)
86. Hukin, J., Epstein, F., Lefton, D. & Allen, J. Treatment of intracranial ependymoma by surgery alone. Pediatr. Neurosurg. 29, 40-45 (1998). (Pubitemid 29060798)
87. Duffner, P. K. et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N. Engl. J. Med. 328, 1725-1731 (1993). (Pubitemid 23170121)
88. Gaynon, P. S. et al. Carboplatin in childhood brain tumors. A Children's Cancer Study group phase II trial. Cancer 66, 2465-2469 (1990).
89. Needle, M. N. et al. Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer 80, 341-347 (1997). (Pubitemid 27282329)
90. Ridley, L. et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol. 10, 675-689 (2008).
91. Tabori, U. et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J. Clin. Oncol. 24, 1522-1528 (2006). (Pubitemid 46638773)
92. Taylor, M. D. et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8, 323-335 (2005). (Pubitemid 41443417)
93. Johnson, R. A. et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466, 632-636 (2010).
94. MacDonald, T. J. et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933 Cancer 104, 2862-2871 (2005). (Pubitemid 41798299)
95. Hales, R. K. et al. Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis. J. Neurooncol 99, 65-71 (2010).
96. Pollack, I. F. et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol. 5, 197-207 (2003). (Pubitemid 36790349)
97. Pollack, I. F. et al. Expression of p53 and prognosis in children with malignant gliomas. N. Engl. J. Med. 346, 420-427 (2002). (Pubitemid 34437697)
98. Pollack, I. F. et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin. Oncol. 24, 3431-3437 (2006). (Pubitemid 46638900)
99. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. .J. Med. 352, 997-1003 (1003).
100. Jakacki, R. I. et al. A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol. 10, 569-576 (2008).
101. Jakacki, R. I. et al. A phase II study of concurrent radiation and temozolomide (TMZ) followed by temozolomide and lomustine (CCNU) in the treatment of children with high grade glioma (HGG): results of COG ACNS0423 Neuro Oncol. 12, ii12 (2010).
102. Pollack, I. et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J. Neurosurg. 105 (Suppl. 5), 418-424 (2006). (Pubitemid 44954773)
103. Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469-474 (2009).
104. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
105. Pollack, I. F. et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv. Syst. 27, 87-94 (2011).
106. Kieran, M. W. et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr. Blood Cancer 52, 169-176 (2009).
107. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17, 98-110 (2010).
108. Paugh, B. S. et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28, 3061-3068 (2010).
109. Okada, H. et al. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J. Neurooncol. 88, 245-250 (2008).
110. Van Gool, S. et al. Dendritic cell therapy of high-grade gliomas. Brain Pathol. 19, 694-712 (2009).
111. Albright, A. L. et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery 33, 1026-1029 (1993).
112. Epstein, F. & McCleary, E. L. Intrinsic brain-stem tumors of childhood: surgical indications. J. Neurosurg. 64, 11-15 (1986). (Pubitemid 16189592)
113. Pollack, I. F., Hoffman, H. J., Humphreys, R. P. & Becker, L. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J. Neurosurg. 78, 859-863 (1993). (Pubitemid 23159320)
114. Freeman, C. R. et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int. J. Radiat. Oncol. Biol. Phys. 27, 197-206 (1993). (Pubitemid 23304443)
115. Packer, R. J. et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer 74, 1827-1834 (1994). (Pubitemid 24301840)
116. Dunkel, I. J. et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group. J. Neurooncol. 37, 67-73 (1998). (Pubitemid 28073577)
117. Jenkin, R. D. et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J. Neurosurg. 66, 227-233 (1987). (Pubitemid 17027880)
118. Kretschmar, C. S. et al. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors. A phase II study of the Pediatric Oncology Group, Protocol 8833 Cancer 72, 1404-1413 (1993).
119. Bernier-Chastagner, V. et al. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. Cancer 104, 2792-2797 (2005). (Pubitemid 41798290)
120. Bradley, K. A. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase 1 study. Neuro Oncol. 10, 752-758 (2008).
121. Haas-Kogan, D. A. et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 13, 298-306 (2011).
122. Pollack, I. F. et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 9, 145-160 (2007). (Pubitemid 46580316)
123. Pollack, I. F. et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 13, 290-297 (2011).
124. Zarghooni, M. et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J. Clin. Oncol. 28, 1337-1344 (2010).
125. Pirotte, B. J. et al. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J. Neurosurg. 107, 392-399 (2007).
126. Roujeau, T. et al. Stereotactic biopsy of diffuse pontine lesions in children. J. Neurosurg. 107, 1-4 (2007).
127. Lonser, R. R. et al. Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J. Neurosurg. 107, 190-197 (2007). (Pubitemid 47026491)
128. Geyer, J. R. et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J. Clin. Oncol. 23, 7621-7631 (2005). (Pubitemid 46291826)
129. Dhall, G. et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the Head Start I and II protocols. Pediatr. Blood Cancer 50, 1169-1175 (2008). (Pubitemid 351555540)
130. Grill, J. et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 6, 573-580 (2005). (Pubitemid 41051935)
131. Ashley, D. M. Systemic chemotherapy, second look surgery and conformal radiation therapy limited to the posterior fossa and primary site for children >8 months and <3 years with nonmetastatic medulloblastoma: A Children's Oncology Group phase III study follow up report. Neuro Oncol. 12, ii6 (2010).
132. Rutkowski, S. et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med. 352, 978-986 (2005). (Pubitemid 40349500)
133. Biegel, J. A. et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59, 74-79 (1999). (Pubitemid 29062960)
134. Eaton, K., Tooke, L. S., Wainwright, L. M., Judkins, A. R., Biegel, J. A. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr. Blood Cancer 56, 7-15 (2011).
135. Judkins, A. R. et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J. Neuropathol. Exp. Neurol. 64, 391-397 (2005). (Pubitemid 40629129)
136. Chi, S. N. et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J. Clin. Oncol. 27, 385-389 (2009).
137. Finkelstein-Shechter, T. et al. Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J. Pediatr. Hematol. Oncol. 23, e182-e186 (2010).
138. Tekautz, T. M. et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J. Clin. Oncol. 23, 1491-1499 (2005).
139. Garre, M. L. et al. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome-a new clinical perspective. Clin. Cancer Res. 15, 2463-2471 (2009).
140. Pollack, I. F. Posterior fossa syndrome. Int. Rev. Neurobiol. 41, 411-432 (1997).
141. Ullrich, N. J. Neurologic sequelae of brain tumors in children. J. Child Neurol. 24, 1446-1454 (2009).
142. Wells, E. M. et al. Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin. J. Neurosurg. Pediatr. 5, 329-334 (2010).
143. Palmer, S. L. et al. Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncol. 12, 1311-1317 (2011).